PAR

Par Drugs & Chemicals Share Price

 

 

Start SIP in PAR

Start SIP
Par Drugs & Chemicals live price: ₹85.65. It opened at ₹84 vs previous close ₹82; intraday high/low: ₹87/₹83. The 50 & 200 DMA stand at ₹90.47/₹104.07.

Par Drugs & Chemicals Performance

  • Today's Low
  • ₹83
  • Today's High
  • ₹87
  • 52 Week Low
  • ₹78
  • 52 Week High
  • ₹122
  • Open Price₹84
  • Previous Close₹82
  • Volume3,757
  • 50 DMA₹90.47
  • 100 DMA₹93.93
  • 200 DMA₹104.07

Investment Returns

  • Over 1 Month -6.41%
  • Over 3 Month -15.31%
  • Over 6 Month -18.37%
  • Over 1 Year -12.01%

Smart Investing Starts Here Start SIP with Par Drugs & Chemicals for Steady Growth!

Invest Now

Par Drugs & Chemicals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 7.6
  • PEG Ratio
  • -0.8
  • Market Cap Cr
  • 105
  • P/B Ratio
  • 0.9
  • Average True Range
  • 4.53
  • EPS
  • 11.3
  • Dividend Yield
  • 0
  • MACD Signal
  • -2.63
  • RSI
  • 45.75
  • MFI
  • 30.23

Par Drugs & Chemicals Financials

Par Drugs & Chemicals Technicals

EMA & SMA

Current Price
₹85.65
+ 3.18 (3.86%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹86.66
  • 50 Day
  • ₹90.47
  • 100 Day
  • ₹93.93
  • 200 Day
  • ₹104.07

Resistance and Support

85.22 Pivot Speed
  • R3 91.43
  • R2 89.22
  • R1 87.43
  • S1 83.43
  • S2 81.22
  • S3 79.43

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Par Drugs and Chemicals has an operating revenue of Rs. 106.37 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 18% is great, ROE of 13% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 56 which is a POOR score indicating inconsistency in earnings, a RS Rating of 49 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 42 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Par Drugs & Chemicals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-10 Quarterly Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-11-13 Quarterly Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-08-29 Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-08-07 Quarterly Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-05-08 Audited Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
Date Purpose Remarks
2021-04-28 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.

Par Drugs & Chemicals F&O

Par Drugs & Chemicals Shareholding Pattern

73.41%
0%
20.03%
6.56%

Par Drugs & Chemicals FAQs

Par Drugs & Chemicals share price is ₹85 As on 07 April, 2026 | 03:28

The Market Cap of Par Drugs & Chemicals is ₹105.4 Cr As on 07 April, 2026 | 03:28

The P/E ratio of Par Drugs & Chemicals is 7.6 As on 07 April, 2026 | 03:28

The PB ratio of Par Drugs & Chemicals is 0.9 As on 07 April, 2026 | 03:28

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23